查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1539341

伽瑪刀市場：2024-2032年全球產業分析、規模、佔有率、成長、趨勢、預測

Gamma Knife Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日期: | 出版商: Persistence Market Research | 英文 102 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research 最近發布了一份關於全球伽瑪刀市場的詳細研究報告，提供了對市場動態（如驅動因素、趨勢、機會和挑戰）的詳細見解。本報告目的是為醫療保健和醫療器材行業的利益相關者提供對市場結構和未來前景的全面了解，特別是關注非侵入性神經外科治療。

關鍵見解

  • 全球市場收入（2022年）：2.041億美元
  • 預計市場價值（2033年）：3.114億美元
  • 全球市場成長率（2022-2033年年複合成長率）：4.8%

伽瑪刀全球市場：研究範圍

伽瑪刀市場主要集中在伽瑪刀機器的生產、分銷和使用，伽瑪刀機器是用於治療腦腫瘤、血管畸形和其他神經系統疾病的非侵入性手術工具。該市場包括目的是透過精確放射外科手術改善患者治療效果的廣泛產品和服務，這些產品和服務能夠在對周圍健康組織影響最小的情況下治療複雜的腦部疾病。

推動市場成長的因素：

腦腫瘤發生率上升及各種合併治療簡介

腦腫瘤發生率的上升和治療方法的進步推動伽瑪刀市場的成長。根據美國癌症協會的資料，腦腫瘤是 40 歲以上人口第八大常見癌症，也是第三大癌症死亡原因。隨著世界人口老化和人口成長，對有效腦腫瘤治療（包括伽瑪刀放射外科手術）的需求預計將會增加。

伽瑪刀放射手術是一種高度針對性的治療方法，可以保留周圍健康的腦組織，特別適合患有多發性腦轉移的患者。伽瑪刀放射外科與生物或免疫製劑結合也越來越受歡迎。例如，醫科達針對黑色素瘤腦轉移的聯合療法結合了免疫療法和伽瑪刀放射外科，顯示出改善的腫瘤控制和患者生存率，凸顯了聯合療法推動市場成長的潛力。

監理機關核准與新產品發布

監管部門的批准和創新產品的採用進一步支持了伽瑪刀市場。例如，Elekta 於2022年 5月發布了 Icon。該伽瑪刀系統透過提供無框架、基於面罩的放射外科手術徹底改變了這個領域。該系統在澳洲等地區特別受歡迎，擴大了大腦 SRS 治療神經系統疾病的能力並推動了市場成長。

市場挑戰：

伽瑪刀放射治療設備成本高，病患意識低

伽瑪刀市場面臨的主要挑戰之一是伽瑪刀設備的高成本以及相關的投資和維護成本。伽瑪刀設備的初始成本明顯高於其他輻射設備，限制了其在新興國家的採用。例如，印度的伽瑪刀手術起價為 6,500 美元，而在西方國家，費用在 40,000 美元至 70,000 美元之間。此外，伽瑪刀裝置中使用的鈷60放射源的成本為100萬美元至200萬美元，並且必須每五年更換一次，增加了總體費用。

此外，美洲和歐洲以外地區伽瑪刀設備的供應有限以及缺乏操作該設備的熟練專業人員也阻礙了市場成長。此外，大眾對伽瑪刀治療的認識仍然較低，許多患者不知道其好處或對治療有誤解。這種意識和理解的缺乏預計將減緩市場成長，特別是在獲得先進醫療技術的機會有限的地區。

本報告解決的關鍵問題

  • 推動全球伽瑪刀市場成長的關鍵因素是什麼？
  • 哪個消費族群引領伽瑪刀治療的採用？
  • 放射外科技術的進步如何影響競爭格局？
  • 誰是全球伽瑪刀市場的主要參與者？ 他們採取哪些策略來維持其市場地位？
  • 全球伽瑪刀市場的新趨勢和未來前景是什麼？

目錄

第1章 執行摘要

第2章 市場概述

  • 市場範圍/分類
  • 市場定義/範圍/限制
  • 包含/排除

第3章 主要市場趨勢

  • 影響市場的主要趨勢
  • 產品創新/發展趨勢

第4章 關鍵成功因素

  • 產品採用/使用分析
  • 產品 USP/特點
  • 安裝基礎場景
  • 技術評估
  • 監理狀況
  • PESTLE分析
  • 波特分析
  • 價值鏈分析

第5章 市場背景

  • 宏觀經濟因素
  • 預測因子 - 相關性和影響
  • 動態

第6章 COVID-19 危機 - 影響評估

  • 新冠肺炎（COVID-19）與影響分析
    • 依疾病分類
    • 依治療目標器官分類
    • 依地區
  • 2024年市場情景

第7章 全球市場需求（金額或規模，百萬美元）分析

  • 2019-2023年過去的市值（百萬美元）分析
  • 2024-2032年當前及未來市場價值（百萬美元）預測
    • 年成長趨勢分析
    • 絕對數量機會分析

第8章 全球市場分析：依疾病分類

  • 簡介/主要發現
  • 2019-2023年歷史市場規模（百萬美元）分析：依疾病
  • 2024-2032年當前和未來市場規模（百萬美元）的分析和預測：依疾病
    • 腦轉移
    • 癌症
    • 動靜脈畸形（AVM）
    • 三叉神經痛
    • 其他
  • 市場吸引力分析：依疾病分類

第9章 全球市場分析：依治療器官

  • 簡介/主要發現
  • 過去市場規模分析（百萬美元）：依治療器官，2019-2023年
  • 2024-2032年當前和未來市場規模（百萬美元）分析和預測：依治療器官
    • 頭
    • 頸部
    • 其他
  • 市場吸引力分析：依治療目標器官分類

第10章 世界市場分析：依地區

  • 簡介
  • 2019-2023年歷史市場規模分析（百萬美元）：依地區
  • 2024-2032年當前和未來市場規模（百萬美元）分析和預測：依地區
    • 北美
    • 拉丁美洲
    • 歐洲
    • 南亞
    • 東亞
    • 大洋洲
    • 中東和非洲（MEA）
  • 市場吸引力分析：依地區

第11章 北美市場分析

第12章 拉丁美洲市場分析

第13章 歐洲市場分析

第14章 南亞市場分析

第15章 東亞市場分析

第16章 大洋洲市場分析

第17章 中東、非洲市場分析

第18章 市場結構分析

  • 市場分析：依公司層級
  • 主要公司市佔率分析
  • 市場現況分析

第19章 競爭分析

  • 競爭儀表板
  • 競爭基準
  • 競爭詳情
    • Elekta AB
    • Varian Medical Systems
    • Huiheng Medical, Inc.
    • MASEP Medical Science Technology Development（Shenzhen）Co., Ltd.
    • Akesis Inc.
    • Cyber Medical Corporation Limited.
    • Masep Infini Global, Inc.
    • Nordion, Inc.
    • Hokai
    • ET Medical Group
    • American Shared Hospital Services

第20章 使用的先決條件與縮寫

第21章 研究方法

簡介目錄
Product Code: PMRREP3742

Persistence Market Research has recently published an in-depth report on the global gamma knife market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and medical device sectors focused on non-invasive neurosurgical treatments.

Key Insights:

  • Global Market Revenue (2022): US$ 204.1 Million
  • Estimated Market Value (2033): US$ 311.4 Million
  • Global Market Growth Rate (CAGR 2022-2033): 4.8%

Global Gamma Knife Market - Report Scope:

The gamma knife market focuses on the production, distribution, and use of gamma knife machines, a non-invasive surgical tool primarily used for treating brain tumors, vascular malformations, and other neurological disorders. This market encompasses a range of products and services aimed at improving patient outcomes through precision radiosurgery, which allows for the treatment of complex brain conditions with minimal impact on surrounding healthy tissues.

Market Growth Drivers:

Rising Prevalence of Brain Tumors Coupled with Introduction of Various Combination Treatment Therapies

The rising incidence of brain tumors, coupled with advancements in treatment modalities, is driving the growth of the gamma knife market. According to the American Cancer Society, brain tumors are the eighth most prevalent type of cancer and the third leading cause of cancer deaths in people aged 40 and older. As the global population ages and expands, the demand for effective brain tumor treatments, including gamma knife radiosurgery, is expected to increase.

Gamma knife radiosurgery offers a highly targeted treatment option that spares surrounding healthy brain tissue, making it particularly suitable for patients with multiple brain metastases. The combination of gamma knife radiosurgery with biological and immunological agents is also gaining traction. For example, Elekta's combination therapy for melanoma brain metastases, which pairs immunotherapy with gamma knife radiosurgery, has shown improved tumor control and patient survival, highlighting the potential for combination treatments to drive market growth.

Regulatory Approvals and New Product Launches

The gamma knife market is further supported by regulatory approvals and the introduction of innovative products. For instance, Elekta introduced the Icon in May 2022, a gamma knife system that revolutionized the field by offering frameless, mask-based radiosurgery. This system has been particularly impactful in regions like Australia, where it has expanded the brain SRS capacity for treating neurological diseases, boosting market growth.

Market Challenges:

High Cost of Gamma Knife Radiotherapy Machines Coupled with Low Awareness of Patients

One of the significant challenges facing the gamma knife market is the high cost of gamma knife machines and the associated investment and maintenance expenses. The initial cost of gamma knife machines is considerably higher than other radiation equipment, which limits adoption in emerging economies. For instance, gamma knife surgery in India starts at USD 6,500, while in Western countries, the price ranges from USD 40,000 to USD 70,000. Additionally, the cobalt-60 radiation source used in gamma knife machines costs between USD 1 million to USD 2 million and requires replacement every five years, contributing to the overall expense.

The market's growth is also hindered by the limited availability of gamma knife machines outside of the Americas and Europe, as well as a shortage of skilled professionals capable of operating the equipment. Furthermore, general awareness of gamma knife treatment remains low, with many patients either unaware of the benefits or harboring misconceptions about the procedure. This lack of awareness and understanding is expected to slow down the market's growth, particularly in regions with limited access to advanced healthcare technologies.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global gamma knife market?
  • Which consumer segments are leading the adoption of gamma knife treatments?
  • How are advancements in radiosurgery technology influencing the competitive landscape?
  • Who are the key players in the global gamma knife market, and what strategies are they employing to maintain their market position?
  • What are the emerging trends and future prospects in the global gamma knife market?

Competitive Intelligence and Business Strategy:

Leading players in the global gamma knife market, such as Elekta AB, Varian Medical Systems, and Accuray Incorporated, are focusing on product innovation, strategic collaborations, and expanding their geographical presence to maintain a competitive edge. These companies are investing heavily in research and development to create advanced gamma knife systems that offer improved precision and patient outcomes. Collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of these technologies. Additionally, targeted marketing and educational campaigns are crucial for increasing patient awareness and acceptance of gamma knife treatments.

Key Companies Profiled:

  • Elekta AB
  • Varian Medical Systems
  • Huiheng Medical, Inc.
  • MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
  • Akesis Inc.
  • Cyber Medical Corporation Limited.
  • Masep Infini Global, Inc.
  • Nordion, Inc.
  • Hokai
  • ET Medical Group
  • American Shared Hospital Services

Key Segments Covered in Gamma Knife Industry Research

Disease Indication:

  • Brain Metastasis
  • Cancer
  • Arteriovenous Malformation (AVM)
  • Trigeminal Neuralgia
  • Others

Organ Treated:

  • Head
  • Neck
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Technology Roadmap
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Install Base Scenario
  • 4.4. Technology Assessment
  • 4.5. Regulatory Landscape
  • 4.6. PESTLE Analysis
  • 4.7. Porter Analysis
  • 4.8. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Radiotherapy Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Prevalence of Obesity
    • 5.2.2. Demand for Non-Invasive Procedures
    • 5.2.3. Growing Burden of Brain Cancer
    • 5.2.4. Increasing Instances of Neurological Disorders
    • 5.2.5. Introduction of Novel Treatment Options
    • 5.2.6. Technological Advancements
    • 5.2.7. Product Adoption Rate
    • 5.2.8. Growing Installed Base
  • 5.3. Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Disease Indication
    • 6.1.2. By Organ Treated
    • 6.1.3. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2024-2032
    • 8.3.1. Brain Metastasis
    • 8.3.2. Cancer
    • 8.3.3. Arteriovenous Malformation (AVM)
    • 8.3.4. Trigeminal Neuralgia
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis By Disease Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Organ Treated

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Organ Treated, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Organ Treated, 2024-2032
    • 9.3.1. Head
    • 9.3.2. Neck
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis By Organ Treated

10. Global Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. South Asia
    • 10.3.5. East Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2019-2023 and Forecast 2024-2032

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Disease Indication
    • 11.3.3. By Organ Treated
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Disease Indication
    • 11.4.3. By Organ Treated
  • 11.5. Country Level Analysis & Forecast
    • 11.5.1. U.S. Market Analysis
      • 11.5.1.1. Introduction
      • 11.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.5.1.2.1. By Disease Indication
        • 11.5.1.2.2. By Organ Treated
    • 11.5.2. Canada Market Analysis
      • 11.5.2.1. Introduction
      • 11.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.5.2.2.1. By Disease Indication
        • 11.5.2.2.2. By Organ Treated
  • 11.6. Market Trends
  • 11.7. Key Market Participants - Intensity Mapping
  • 11.8. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 12.3.1. By Country
      • 12.3.1.1. Brazil
      • 12.3.1.2. Mexico
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Disease Indication
    • 12.3.3. By Organ Treated
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Disease Indication
    • 12.4.3. By Organ Treated
  • 12.5. Country Level Analysis & Forecast
    • 12.5.1. Brazil Market Analysis
      • 12.5.1.1. Introduction
      • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.1.2.1. By Disease Indication
        • 12.5.1.2.2. By Organ Treated
    • 12.5.2. Mexico Market Analysis
      • 12.5.2.1. Introduction
      • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.2.2.1. By Disease Indication
        • 12.5.2.2.2. By Organ Treated
    • 12.5.3. Argentina Market Analysis
      • 12.5.3.1. Introduction
      • 12.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.3.2.1. By Disease Indication
        • 12.5.3.2.2. By Organ Treated
  • 12.6. Market Trends
  • 12.7. Key Market Participants - Intensity Mapping
  • 12.8. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. France
      • 13.3.1.3. Italy
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. Russia
      • 13.3.1.7. BENELUX
      • 13.3.1.8. Nordic Countries
      • 13.3.1.9. Rest of Europe
    • 13.3.2. By Disease Indication
    • 13.3.3. By Organ Treated
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Disease Indication
    • 13.4.3. By Organ Treated
  • 13.5. Country Level Analysis & Forecast
    • 13.5.1. Germany Market Analysis
      • 13.5.1.1. Introduction
      • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.1.2.1. By Disease Indication
        • 13.5.1.2.2. By Organ Treated
    • 13.5.2. France Market Analysis
      • 13.5.2.1. Introduction
      • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.2.2.1. By Disease Indication
        • 13.5.2.2.2. By Organ Treated
    • 13.5.3. Italy Market Analysis
      • 13.5.3.1. Introduction
      • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.3.2.1. By Disease Indication
        • 13.5.3.2.2. By Organ Treated
    • 13.5.4. U.K. Market Analysis
      • 13.5.4.1. Introduction
      • 13.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.4.2.1. By Disease Indication
        • 13.5.4.2.2. By Organ Treated
    • 13.5.5. Spain Market Analysis
      • 13.5.5.1. Introduction
      • 13.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.5.2.1. By Disease Indication
        • 13.5.5.2.2. By Organ Treated
    • 13.5.6. Russia Market Analysis
      • 13.5.6.1. Introduction
      • 13.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.6.2.1. By Disease Indication
        • 13.5.6.2.2. By Organ Treated
    • 13.5.7. Nordic Countries Market Analysis
      • 13.5.7.1. Introduction
      • 13.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.7.2.1. By Disease Indication
        • 13.5.7.2.2. By Organ Treated
    • 13.5.8. BENELUX Market Analysis
      • 13.5.8.1. Introduction
      • 13.5.8.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.8.2.1. By Disease Indication
        • 13.5.8.2.2. By Organ Treated
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. India
      • 14.3.1.2. Thailand
      • 14.3.1.3. Indonesia
      • 14.3.1.4. Malaysia
      • 14.3.1.5. Rest of South Asia
    • 14.3.2. By Disease Indication
    • 14.3.3. By Organ Treated
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Disease Indication
    • 14.4.3. By Organ Treated
  • 14.5. Country Level Analysis & Forecast
    • 14.5.1. India Market Analysis
      • 14.5.1.1. Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Disease Indication
        • 14.5.1.2.2. By Organ Treated
    • 14.5.2. Thailand Market Analysis
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Disease Indication
        • 14.5.2.2.2. By Organ Treated
    • 14.5.3. Indonesia Market Analysis
      • 14.5.3.1. Introduction
      • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.3.2.1. By Disease Indication
        • 14.5.3.2.2. By Organ Treated
    • 14.5.4. Malaysia Market Analysis
      • 14.5.4.1. Introduction
      • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.4.2.1. By Disease Indication
        • 14.5.4.2.2. By Organ Treated
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Disease Indication
    • 15.3.3. By Organ Treated
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Disease Indication
    • 15.4.3. By Organ Treated
  • 15.5. Country Level Analysis & Forecast
    • 15.5.1. China Market Analysis
      • 15.5.1.1. Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Disease Indication
        • 15.5.1.2.2. By Organ Treated
    • 15.5.2. Japan Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Disease Indication
        • 15.5.2.2.2. By Organ Treated
    • 15.5.3. South Korea Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Disease Indication
        • 15.5.3.2.2. By Organ Treated
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Disease Indication
    • 16.3.3. By Organ Treated
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Disease Indication
    • 16.4.3. By Organ Treated
  • 16.5. Country Level Analysis & Forecast
    • 16.5.1. Australia Market Analysis
      • 16.5.1.1. Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Disease Indication
        • 16.5.1.2.2. By Organ Treated
    • 16.5.2. New Zealand Market Analysis
      • 16.5.2.1. Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Disease Indication
        • 16.5.2.2.2. By Organ Treated
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkiye
      • 17.3.1.3. Northern Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Disease Indication
    • 17.3.3. By Organ Treated
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Disease Indication
    • 17.4.3. By Organ Treated
  • 17.5. Country Level Analysis & Forecast
    • 17.5.1. GCC Countries Market Analysis
      • 17.5.1.1. Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Disease Indication
        • 17.5.1.2.2. By Organ Treated
    • 17.5.2. Turkiye Market Analysis
      • 17.5.2.1. Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Disease Indication
        • 17.5.2.2.2. By Organ Treated
    • 17.5.3. Northern Africa Market Analysis
      • 17.5.3.1. Introduction
      • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.3.2.1. By Disease Indication
        • 17.5.3.2.2. By Organ Treated
    • 17.5.4. South Africa Market Analysis
      • 17.5.4.1. Introduction
      • 17.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.4.2.1. By Disease Indication
        • 17.5.4.2.2. By Organ Treated
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Benchmarking
  • 19.3. Competition Deep Dive
    • 19.3.1. Elekta AB
      • 19.3.1.1. Overview
      • 19.3.1.2. Disease Indication Portfolio
      • 19.3.1.3. Key Financials
      • 19.3.1.4. Sales Footprint
      • 19.3.1.5. SWOT Analysis
      • 19.3.1.6. Strategy Overview
        • 19.3.1.6.1. Marketing Strategy
        • 19.3.1.6.2. Product Strategy
        • 19.3.1.6.3. Channel Strategy
    • 19.3.2. Varian Medical Systems
      • 19.3.2.1. Overview
      • 19.3.2.2. Disease Indication Portfolio
      • 19.3.2.3. Key Financials
      • 19.3.2.4. Sales Footprint
      • 19.3.2.5. SWOT Analysis
      • 19.3.2.6. Strategy Overview
        • 19.3.2.6.1. Marketing Strategy
        • 19.3.2.6.2. Product Strategy
        • 19.3.2.6.3. Channel Strategy
    • 19.3.3. Huiheng Medical, Inc.
      • 19.3.3.1. Overview
      • 19.3.3.2. Disease Indication Portfolio
      • 19.3.3.3. Key Financials
      • 19.3.3.4. Sales Footprint
      • 19.3.3.5. SWOT Analysis
      • 19.3.3.6. Strategy Overview
        • 19.3.3.6.1. Marketing Strategy
        • 19.3.3.6.2. Product Strategy
        • 19.3.3.6.3. Channel Strategy
    • 19.3.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
      • 19.3.4.1. Overview
      • 19.3.4.2. Disease Indication Portfolio
      • 19.3.4.3. Key Financials
      • 19.3.4.4. Sales Footprint
      • 19.3.4.5. SWOT Analysis
      • 19.3.4.6. Strategy Overview
        • 19.3.4.6.1. Marketing Strategy
        • 19.3.4.6.2. Product Strategy
        • 19.3.4.6.3. Channel Strategy
    • 19.3.5. Akesis Inc.
      • 19.3.5.1. Overview
      • 19.3.5.2. Disease Indication Portfolio
      • 19.3.5.3. Key Financials
      • 19.3.5.4. Sales Footprint
      • 19.3.5.5. SWOT Analysis
      • 19.3.5.6. Strategy Overview
        • 19.3.5.6.1. Marketing Strategy
        • 19.3.5.6.2. Product Strategy
        • 19.3.5.6.3. Channel Strategy
    • 19.3.6. Cyber Medical Corporation Limited.
      • 19.3.6.1. Overview
      • 19.3.6.2. Disease Indication Portfolio
      • 19.3.6.3. Key Financials
      • 19.3.6.4. Sales Footprint
      • 19.3.6.5. SWOT Analysis
      • 19.3.6.6. Strategy Overview
        • 19.3.6.6.1. Marketing Strategy
        • 19.3.6.6.2. Product Strategy
        • 19.3.6.6.3. Channel Strategy
    • 19.3.7. Masep Infini Global, Inc.
      • 19.3.7.1. Overview
      • 19.3.7.2. Disease Indication Portfolio
      • 19.3.7.3. Key Financials
      • 19.3.7.4. Sales Footprint
      • 19.3.7.5. SWOT Analysis
      • 19.3.7.6. Strategy Overview
        • 19.3.7.6.1. Marketing Strategy
        • 19.3.7.6.2. Product Strategy
        • 19.3.7.6.3. Channel Strategy
    • 19.3.8. Nordion, Inc.
      • 19.3.8.1. Overview
      • 19.3.8.2. Disease Indication Portfolio
      • 19.3.8.3. Key Financials
      • 19.3.8.4. Sales Footprint
      • 19.3.8.5. SWOT Analysis
      • 19.3.8.6. Strategy Overview
        • 19.3.8.6.1. Marketing Strategy
        • 19.3.8.6.2. Product Strategy
        • 19.3.8.6.3. Channel Strategy
    • 19.3.9. Hokai
      • 19.3.9.1. Overview
      • 19.3.9.2. Disease Indication Portfolio
      • 19.3.9.3. Key Financials
      • 19.3.9.4. Sales Footprint
      • 19.3.9.5. SWOT Analysis
      • 19.3.9.6. Strategy Overview
        • 19.3.9.6.1. Marketing Strategy
        • 19.3.9.6.2. Product Strategy
        • 19.3.9.6.3. Channel Strategy
    • 19.3.10. ET Medical Group
      • 19.3.10.1. Overview
      • 19.3.10.2. Disease Indication Portfolio
      • 19.3.10.3. Key Financials
      • 19.3.10.4. Sales Footprint
      • 19.3.10.5. SWOT Analysis
      • 19.3.10.6. Strategy Overview
        • 19.3.10.6.1. Marketing Strategy
        • 19.3.10.6.2. Product Strategy
        • 19.3.10.6.3. Channel Strategy
    • 19.3.11. American Shared Hospital Services
      • 19.3.11.1. Overview
      • 19.3.11.2. Disease Indication Portfolio
      • 19.3.11.3. Key Financials
      • 19.3.11.4. Sales Footprint
      • 19.3.11.5. SWOT Analysis
      • 19.3.11.6. Strategy Overview
        • 19.3.11.6.1. Marketing Strategy
        • 19.3.11.6.2. Product Strategy
        • 19.3.11.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology